

# pharmaceutical research

 **aaps** An Official Journal of the American Association of Pharmaceutical Scientists

## THE *PHARMACEUTICAL RESEARCH* INSTRUCTIONS FOR AUTHORS

### ACCEPTED ARTICLE SPECIFICATIONS

*Pharmaceutical Research* does not charge page or color fees. The journal publishes the following article types:

Article Type	Structured Abstract*	Max Word Count**	Description	Tables/Figures Combined (maximum)	References (maximum)
Original Research Article	Yes	6,000	Contain innovative, hypothesis-driven research that is supported by sound experimental design, methodology, and data interpretation. May include supplementary material.	No limit	100
Review Article	Yes	8,000	Usually by invitation and organized into themes, report on recent advances in pharmaceutical research. May include supplementary material.	No limit	300
Editorial	No abstract necessary	1,000	These articles contain topical issues of public and scientific interest. May include supplementary material.	No limit	n/a
Perspective	No abstract necessary	2,500	These articles contain research discussion and professional opinions of scientific interest.	2	20
Correction	No abstract necessary		Correction requests should be sent to the editorial office with proposed correction text. See below for our correction policies.		

\*Abstracts should not exceed 250 words and must be structured.

\*\*Word count may be flexible, on editor's discretion. It includes the abstract and full text, but not references, figures, or tables.

*Pharmaceutical Research* also publishes theme issues, organized by guest editors, which are focused on particular areas of current interest to the field.

## **SUBMISSION CHECKLIST AND MANUSCRIPT PREPARATION**

Authors can use the below for a Submission Checklist. All submissions should be formatted in the following order. For further information on each, see the descriptions in the sections immediately below.

1. Cover Letter
2. Article File
  - a. Title page
  - b. Abstract (See “Article Type Specifications,” above, for directions) and Introduction
  - c. Materials and Methods
  - d. Results (or Results and Discussion)
  - e. Discussion
  - f. Conclusion
  - g. References (listed by number, in order of appearance)
  - h. Acknowledgements
  - i. Funding statement
  - j. Conflict of Interest statement
  - k. [Optional] Author contributions for all authors
  - l. [Optional] Data availability statement
  - m. Figure legends (Figures should be uploaded as separate attachments; permission for any which are not original should be obtained by authors)
3. Tables
4. Figures\*\*
5. Supplemental material
6. Other: Reporting guidelines

## **Manuscript Preparation: General Notes and Description of Each Section**

### **General Notes**

It is important that papers are prepared in the general editorial style of the journal. Please note:

- Acceptable file formats include .doc, .docx, LaTeX, and .rtf, Please do not upload .pdf files.
  - A note on LaTeX: If using, please use Springer's [LaTeX macro package](#) and choose the formatting option “smallexended”. The submission should include the original source (including all style files and figures) and a PDF version of the compiled output.
- Use abbreviations sparingly, and define them at the first insertion in the text. Define all abbreviations used in tables within the table footnotes.
- Please avoid using more than three levels of headings.
- Footnotes should be avoided.
- Use the metric system for all measurements. Express metric abbreviations in lowercase letters without periods (cm, mL, sec). Define all symbols used in equations and formulas. When symbols are used extensively, the authors may include a list of all symbols before the Introduction.
- Numbers should be reported to reflect the precision of the instrumentation utilized. Calculated numbers, such as means and standard deviations, should be expressed to no more than one significant digit beyond the precision of the instrument. Normally, numerical data reported to more than 3 significant figures should be justified.
- The term “significant” should not be used unless statistically analyses were performed, and the probability value used to identify significance (generally P values) should be specified.

- Use SI units throughout.
- Commas should be used to separate thousands.

## **Description of each section**

### *Cover Letter*

The cover letter should explicitly state that the manuscript has not been previously published in any language anywhere and that it is not under simultaneous consideration by another journal. Authors may also use the cover letter to explain why the manuscript is suitable for publication in *Pharmaceutical Research* or to communicate any additional information of relevance.

### *Title page*

The title page should include the title of the article, authors' full first and last names (no degrees), and affiliations. Authors' affiliations should include the department, institution (usually university or company), city, and state (or nation) and should be included as a footnote to the authors' name. Please indicate the corresponding author designated to receive all communications and review proofs, and provide their mailing address, telephone number, and e-mail address.

The author should suggest no more than five keywords on the title page. To ensure that your manuscript is easily searchable in PubMed and other repositories, be sure to include any relevant keywords in the title or abstract of your manuscript.

### *Abstract and Introduction*

See table above for abstract requirements. The introduction should assume that the reader is knowledgeable in the field and should therefore be brief; it can include a short historical review where desirable. It should also include the study objective.

### *Materials and Methods*

This section should contain sufficient detail such that all experimental procedures can be reproduced, and include references. Methods that have been published in detail elsewhere should not be described in detail. Authors should provide the name of the manufacturer and their location for any specifically named equipment and instruments, and all drugs should be identified by their pharmaceutical names, with their trade name, if relevant, in parentheses following, at first use.

An accurate description of each set of data that is shown must be provided and must include the number of biological replicates, the number of experiments performed, and the description and use of appropriate statistical methods (Also see "Data Availability" section, below).

Please carefully read the "Editorial Policies" section for links to information about animal handling, informed consent, and IRB approval, which, wherever applicable, needs to be explicitly disclosed in this section.

### *Results and Discussion*

The Results section should briefly present the experimental data in text, tables or figures. Tables and figures should not be described extensively in the text. The Discussion should focus on the interpretation and the significance of the findings with concise objective comments that describe their relation to other work in the area. It should not repeat information in the results.

### *Conclusions*

The conclusions section should highlight the main conclusion(s), stating the answer to the study objective. The Conclusions section should be a distinct section.


## References

*Pharmaceutical Research* follows Vancouver style for references; specifically, the journal cites references in order of appearance, in a "References" list. In the text, numbers should be in parentheses, e.g., "Several studies (1–4, 12)..." Include all authors up to six. If there are more than six authors, list the first six followed by "et al." Periodical abbreviations should follow those used by *Index Medicus*.

Number all references cited in the text first; if additional references are cited in figure legends and tables, add them to the end of the reference list.

If using Endnote, please choose the style Springer Vancouver Number (see inset).

Examples for references are below:



- Journal article  
Smith JJ. The world of science. *Am J Sci*. 1999;36:234–5.
- Journal article with DOI (and with page numbers)  
O'Mahony S, Rose SL, Chilvers AJ, Ballinger JR, Solanki CK, Barber RW, et al. Finding an optimal method for imaging lymphatic vessels of the upper limb. *Eur J Nucl Med Mol Imaging*. 2004;31:555–63.  
<https://doi.org/10.1007/s00259-003-1399-3>.
- Article in electronic journal by DOI (no paginated version)  
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. *Dig J Mol Med*. 2000.  
<https://doi.org/10.1007/s801090000086>.
- Journal article in a supplement  
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity by bone marrow scan. *Blood*. 1979;59 Suppl 1:26–32.
- Book chapter  
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. *International review of cytology*. London: Academic; 1980. p. 251–306.
- Online First chapter in a series (without a volume designation but with a DOI)  
Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral symmetry breaking. *Top Curr Chem*. 2007. [https://doi.org/10.1007/128\\_2006\\_108](https://doi.org/10.1007/128_2006_108).
- Book, authored  
Blenkinsopp A, Paxton P. *Symptoms in the pharmacy: a guide to the management of common illness*. 3rd ed. Oxford: Blackwell Science; 1998.
- Online document  
Doe J. Title of subordinate document. In: *The dictionary of substances and their effects*. Royal Society of Chemistry. 1999. [http://www.rsc.org/dose/title of subordinate document](http://www.rsc.org/dose/title%20of%20subordinate%20document). Accessed 15 Jan 1999.
- Online database  
Healthwise Knowledgebase. *US Pharmacopeia*, Rockville. 1998. <http://www.healthwise.org>. Accessed 21 Sept 1998.
- Supplementary material/private homepage  
Doe J. Title of supplementary material. 2000. <http://www.privatehomepage.com>. Accessed 22 Feb 2000.
- University site  
Doe, J.: Title of preprint. <http://www.uniheidelberg.de/mydata.html> (1999). Accessed 25 Dec 1999.
- Preprint  
Babichev, S. A., Ries, J. & Lvovsky, A. I. Quantum scissors: teleportation of single-mode optical states by means of a nonlocal single photon. Preprint at <http://arxiv.org/abs/quant-ph/0208066> (2002).

Note: Personal communications should simply be referred to in the text (“Brown et al., personal communication”); the authors must obtain permission from the individual concerned to quote their unpublished work.

### ***Acknowledgements***

This section is optional and is for special thanks or dedications. Work done by a contributor or medical writer that does not qualify them for authorship, but which warrants acknowledgement, should be noted here. Funding information does not belong in this section, but instead in the “Funding” section below. Acknowledgements will be published as part of the article.

### ***Funding Statement***

The Funding section is mandatory. Authors must declare sources of study funding including sponsorship (e.g., university, charity, commercial organization) and sources of material (e.g., novel drugs) not available commercially. See the “Financial Interests and Transparency” section in “Editorial Policy” for further information. The Funding Statement will be published as part of the article.

### ***Conflict of Interest Statement***

This section is also mandatory; in this section, authors must disclose their particular financial relationships to the work described. This information will be published as part of the paper. See the “Financial Interests and Transparency” section in “Editorial Policy” for further information.

### ***Author Contributions***

A statement outlining each author’s contributions is requested. In order to meet requirements of authorship, each author must have contributed to at least one of the aspects below. The [ICMJE](#) and *Pharmaceutical Research* considers authorship to be based on the following four criteria:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and
- Drafting the work or revising it critically for important intellectual content; and
- Final approval of the version to be published; and
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Additional information can be found under “Editorial Policies > Authorship.” As per ICMJE best practice, information provided in this section is the responsibility of the authors. This Author Contributions section will be published as part of the article.

### ***Data Availability Statement***

The journal encourages authors to provide a statement of data availability in their article. Data availability statements should include information on where data supporting the results reported in the article can be found, including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. Data availability statements can also indicate whether data are available on request from the authors and where no data are available, if appropriate.

Data availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets) as examples:

- “The datasets generated during and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]”
- “The datasets generated during and/or analysed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.”

- “The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.”
- “Data sharing not applicable to this article as no datasets were generated or analysed during the current study.”
- “All data generated or analysed during this study are included in this published article [and its supplementary information files].”

## **Tables, Figures, and Supplementary/ Other Files**

It is the authors' responsibility to ensure that they have obtained permissions for the use of tables or figures, used in their manuscript, which they do not expressly own.

### *Tables*

Tables must be created in Microsoft Word table format. Tables should be numbered (with Roman numerals) and referred to by number in the text. Center the title above the table, and type explanatory footnotes (indicated by superscript lowercase letters) below the table. Data must be placed in separate cells of the table to prevent text and numbers from shifting when the table is converted for publication online. Empty cells may be inserted to create spacing. Each table should be self-explanatory.

### *Figures*

Color is free in all versions of the article. For full specifications on Figures and Artwork, please visit the below links:

- [Electronic figure submission](#)
- [Line Art](#)
- [Halftone Art](#)
- [Combination Art](#)
- [Color Art](#)
- [Figure Numbering](#)
- [Figure Captions](#)
- [Figure Placement and Size](#)
- [Important: Figure Permissions](#)

### *Supplementary Files*

Supplementary information is material directly relevant to the conclusion of an article that cannot be included in the printed version owing to space or format constraints. It is posted on the journal's web site and linked to the article when the article is published. It may consist of data files, graphics, movies, or extensive tables.

Please visit the below for further information on supplementary information:

- [Submission](#)
- [Audio, Video, and Animations](#)
- [Text and Presentations](#)
- [Spreadsheets](#)
- [Specialized Formats](#)
- [Collecting Multiple Files](#)
- [Numbering](#)
- [Captions](#)
- [Processing](#)
- [Accessibility](#)

## **Other files: Reporting guidelines**

The relevant [EQUATOR Network reporting guidelines](#) should be followed, depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed [Consolidated Standards of Reporting Trials \(CONSORT\) flow chart as a figure, and a completed CONSORT checklist](#) as a Supplementary file.

## **SUBMISSION, SCREENING, AND POST-DECISION**

Submissions to *Pharmaceutical Research* should be done via the journal's [submission portal here](#). Authors should visit that webpage for author tutorials, login options, contacts for the helpdesk, and information on resetting their password, among other things.

After you have approved the PDF of your manuscript, it will be screened to ensure that all components have been submitted. Screened manuscripts then undergo an initial review, during which the Editor-in-Chief will either reject the manuscript if its quality and content are not in line with the aims of *Pharmaceutical Research*, or pass it along to an appropriate editor for further review. Papers that may not be granted a full review include, but are not limited to, those that are routine, are descriptive, are deficient in presentation, offer no insight, or appeal to a specialty audience.

For more information about our peer review policies, please review the "Editorial Policies" section of these guidelines.

Once the manuscript is assessed by the editorial team and following the review process, it may receive an accept decision. If that is the case, it will progress through Editorial Manager to the MyPublication portal, which guides the corresponding author through a workflow which enables the author to stay in communication with us and complete a number of requisite tasks, including choice of color, offprints, open access, and deposition, among others. More information about the [MyPublication process can be found here](#). A short while after completing the MyPublication questionnaire, the author will receive the article's proofs.

## **SELF-ARCHIVING AND OPEN ACCESS**

### **Self-archiving and manuscript deposition (green open access)**

By signing the copyright form during MyPublication, authors still retain substantial rights, such as self-archiving.

[Visit here](#) to learn more about those rights and the 12-month embargo period before public availability. With *Pharmaceutical Research*, authors have the right to themselves make their Author's Accepted Manuscript (the version of the manuscript post-accept but prior to copyediting and typesetting) publically available on their employer's internal website, their institutional repository, and/or a funder's repository.

Authors with certain funding can also take advantage of the publisher's deposition service. [Learn more about that service here](#).

### **Open access publication (gold open access)**

In MyPublication, authors can indicate whether they wish to make their article open access online immediately upon publication, an option which will incur a fee or "Article Processing Charge" (APC). Open access articles are published under Creative Commons licenses, which allow authors to retain copyright to their work while making it open to readers, and depending on funder mandate, these open access articles are also deposited, by us, to select funder repositories.

Visit our [open research site](#) for further information about licenses, APCs, and our free OA funding support service:

- [Article processing charges for \*Pharmaceutical Research\*](#)
- [Funding support service](#)
- [Help in identifying funding for APCs](#)
- [OA Publication policies](#)

Government employees from the United States, UK, and Canada are required to sign and submit the relevant government open access copyright form.

## EDITORIAL POLICIES

*Pharmaceutical Research* is committed to maintaining high standards for the integrity of the published scientific record. The journal will investigate any instances of suspected scientific fraud, image manipulation, plagiarism, duplicate publication, undocumented sources of funding or conflicts of interest, and other cases that compromise research ethics or the journal's scientific integrity.

Provided here are quicklinks to each of the journal policies:

- [Editorial Policies](#)
- [Appeals and Complaints](#)
- [Authorship Principles](#)
- [Biosafety and Biosecurity](#)
- [Competing Interests](#)
- [Complementary and Alternative Medicine Standards for Research](#)
- [Corrections and Retractions](#)
- [Data Availability Statement](#) (See below for this journal's "Data Policy")
- [Ethical responsibilities of authors](#)
- [Informed Consent](#)
- [List of Recommended Repositories](#)
- [Portable Peer Review](#)
- [Predatory Journals and References](#)
- [Preprint Sharing](#)
- [Policy, Process and Guidance for Peer Reviewers](#)
- [Research involving animals, and their data or biological material](#)
- [Research Involving Human Participants, their Data or Biological Material](#)
- [Research Involving Human Embryos](#)
- [Sex and Gender in Research \(SAGER Guidelines\)](#)
- [Utilization of plants, algae, fungi](#)

### ***Pharmaceutical Research* data policy**

#### *Analysis*

For representative single experiments, by submitting to the journal, authors agree to make available all of the replicate data upon request, if not before. *Pharmaceutical Research* will not publish any manuscript unless the chemical structures of all compounds are fully disclosed, either by reference to prior work providing such data, by linking to a repository where the data is held (more information on this immediately below), or by enclosure of such data in the manuscript. Exceptions are granted only after consulting with the Editor-in-Chief.

#### *Policy*

*Pharmaceutical Research* adheres to Springer Nature's [Research Data Policy Type 1](#). The journal encourages authors, where possible and applicable, to deposit data that support the findings of their research in a public repository. Authors and editors who do not have a preferred repository should consult Springer Nature's list of repositories and research data policy.

- [List of Repositories](#)
- [Research Data FAQs](#)

General repositories - for all types of research data - such as figshare and Dryad - may also be used.

Datasets that are assigned digital object identifiers (DOIs) by a data repository may be cited in the reference list. Data citations should include the minimum information recommended by [DataCite](#): authors, title, publisher (repository name), identifier.

Springer Nature provides a research data policy support service for authors and editors, which can be contacted via the [Helpdesk](#), which provides advice on research data policy compliance and on finding research data repositories. It is independent of journal editorial offices, and does not advise on specific manuscripts.

## English language editing and support

For editors and reviewers to accurately assess the work presented in your manuscript, authors need to ensure the English language is of sufficient quality to be understood. If authors need help with writing in English, they should consider:

- Asking a colleague who is a native English speaker to review the manuscript for clarity.
- Visiting the [English language tutorial](#) which covers the common mistakes when writing in English.
- Using a professional language editing service where editors will improve the English to ensure that their meaning is clear and identify language problems that require your review. Two such services are provided by our affiliates [Nature Research Editing Service](#) and [American Journal Experts](#).

Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted. If a manuscript is accepted, it will be checked by our copyeditors for spelling and formal style before publication, but major language editing will not be undertaken; thus, it is essential articles are of sufficient English quality prior to acceptance.

## Financial Interests and Transparency

*Pharmaceutical Research* values full transparency, and expects authors to disclose funding for the research, the authors' financial relationships to the research, and to acknowledge any special thanks or support for those whose contributions were meaningful.

Failure to disclose funding and any perceived financial interest is considered publication misconduct, and will result in remedial and/or serious action by the journal, guided by [COPE recommendations](#). When there is uncertainty about what should be listed, it is best to disclose all holdings or affiliations to ensure that there is no question about intent to withhold information. Authors should communicate with the editorial office if they have any questions.

Below, prospective *Pharmaceutical Research* authors can find three distinct sections with the description of what belongs in each (also found in the Manuscript Preparation section, above):

- *Acknowledgements*: This section is optional and is for special thanks or dedications. Work done by a contributor or medical writer that does not qualify them for authorship, but which warrants acknowledgement, should be noted here. Funding information does not belong in this section, but instead in the "Funding" section below.
- *Funding Statement*: The Funding section is mandatory. Authors must declare sources of study funding including sponsorship (e.g., university, charity, commercial organization) and sources of material (e.g., novel drugs) not available commercially. More information on this section [can be found here](#).
- *Conflict of Interest Statement*: This section is also mandatory; in this section, authors must disclose their particular financial relationships to the work described. This information will be published as part of the paper. They should include any of the following:
  - Research support (including salaries, equipment, supplies, reimbursement for attending symposia, and other expenses) by organizations that may gain or lose financially through this publication.
  - Employment: Recent (while engaged in the research project), present, or anticipated employment by any organization that may gain or lose financially through this publication.

- Personal financial interests: Stocks or shares in companies that may gain or lose financially through publication.
  - Consultation fees or other forms of remuneration from organizations that may gain or lose financially from publication.
  - Patents or patent applications whose value may be affected by publication.
- More information on the Conflict of Interest section [can be found here](#).

## Image integrity and standards

Images submitted with a manuscript for review should be minimally processed (for instance, to add arrows to a micrograph). Authors should retain their unprocessed data and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data are unavailable, manuscript evaluation may be stalled until the issue is resolved. All digitized images submitted with the final revision of the manuscript must be of high quality and have resolutions of at least 300 d.p.i. for color.

A certain degree of image processing is acceptable for publication (and for some experiments, fields, and techniques is unavoidable), but the final image must correctly represent the original data and conform to community standards. The guidelines below will aid in accurate data presentation at the image processing level; authors must also take care to exercise prudence during data acquisition, where misrepresentation must equally be avoided.

- Authors should list all image acquisition tools and image processing software packages used. Authors should document key image-gathering settings and processing manipulations in the Methods.
- Images gathered at different times or from different locations should not be combined into a single image, unless it is stated that the resultant image is a product of time-averaged data or a time-lapse sequence. If juxtaposing images is essential, the borders should be clearly demarcated in the figure and described in the legend.
- The use of touch-up tools, such as cloning and healing tools in Photoshop, or any feature that deliberately obscures manipulations, must be avoided.
- Processing (such as changing brightness and contrast) is appropriate **only when it is applied equally across the entire image and is applied equally to controls**. Contrast should not be adjusted so that data disappear. Excessive manipulations, such as processing to emphasize one region in the image at the expense of others (for example, through the use of a biased choice of threshold settings), is inappropriate, as is emphasizing experimental data relative to the control.

Further guidance can be found below on the following points:

- [Electrophoretic gels and blots](#)
- [Microscopy](#)
- [Useful editorials on the topic](#)

Pharmaceutical Research

An Official Journal of the American Association of  
Pharmaceutical Scientists

Editor-in-Chief: Li, T.

ISSN: 0724-8741 (print version)

ISSN: 1573-904X (electronic version)

Journal no. 11095